0001615219-15-000047.txt : 20150901
0001615219-15-000047.hdr.sgml : 20150901
20150901172036
ACCESSION NUMBER: 0001615219-15-000047
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150831
FILED AS OF DATE: 20150901
DATE AS OF CHANGE: 20150901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Flex Pharma, Inc.
CENTRAL INDEX KEY: 0001615219
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465087339
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 800 BOYLSTON STREET
STREET 2: 24TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02199
BUSINESS PHONE: 617-874-1821
MAIL ADDRESS:
STREET 1: 800 BOYLSTON STREET
STREET 2: 24TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02199
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Westphal Christoph H
CENTRAL INDEX KEY: 0001291961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36812
FILM NUMBER: 151088022
MAIL ADDRESS:
STREET 1: C/O ALNYLAM PHARMACEUTICALS, INC
STREET 2: 300 THIRD STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
4
1
wf-form4_144114242638458.xml
FORM 4
X0306
4
2015-08-31
0
0001615219
Flex Pharma, Inc.
FLKS
0001291961
Westphal Christoph H
C/O FLEX PHARMA, INC.
800 BOYLSTON STREET
BOSTON
MA
02199
1
1
1
0
President and CEO
Common Stock
2015-08-31
4
P
0
887
12.495
A
3912328
D
Common Stock
2697264
I
By Longwood Fund II. L.P.
The purchase reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2015.
Longwood Fund II GP, LLC is the ultimate General Partner of Longwood Fund II, L.P. Christoph Westphal, M.D., Ph.D., Richard Aldrich and Michelle Dipp, M.D., Ph.D. (collectively, the "Managers") are managers of Longwood Fund II GP, LLC, and, as such, may be deemed to have shared voting and dispositive power with respect to the issuer's securities held by Longwood Fund II, L.P. (the "Longwood Shares"). Each of the Managers disclaims beneficial ownership of the Longwood Shares, except to the extent of their respective pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of Section 16 or for any other purpose.
/s/ Robert Hadfield, Attorney-in-Fact
2015-09-01